Robafen Cough

Quick links to important sections

Robafen Cough

Treatment option: Cough

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Robafen Cough

Property Description
Active ingredient Dextromethorphan Hydrobromide
Form Oral Solution (Cough Syrup)
Pharmacological class Antitussive Agent (Cough suppressant)
Common use Temporary relief of nonproductive cough
Origin Synthetic (Non-narcotic analogue)

The Identity and Classification of Robafen Cough

Robafen Cough is an Over-The-Counter (OTC) preparation that is formally classified as a cough suppressant, belonging to the Antitussive Agents pharmacological class. This designation identifies the medicine as one primarily intended to control the cough reflex in the body. Its essential function is to provide temporary relief from coughing episodes, making it an accessible, non-prescription option for managing minor respiratory irritation. The core formulation is a single-ingredient product, which distinguishes its targeted action from combination products that address multiple cold symptoms.

Composition: Dextromethorphan HBr, Origin, and Form

The defining active ingredient in Robafen Cough is Dextromethorphan Hydrobromide (Dextromethorphan HBr). This compound is a synthetic molecule, specifically a methylated dextrorotary analogue, that is chemically derived but explicitly categorized as a non-narcotic substance. The active ingredient is utilized due to its antitussive properties without the potential for dependency associated with opioids. Robafen Cough is typically provided as an Oral Solution or Oral Liquid (cough syrup), a liquid dosage form designed for convenient and efficient oral administration.

What is the General Purpose of Robafen Cough?

The general therapeutic purpose of Robafen Cough is the temporary suppression of the cough reflex to alleviate associated discomfort. It works by producing a central action on the nervous system, specifically operating to increase the body's cough threshold within the medullary cough center of the brain. The medicine is utilized for managing persistent, nonproductive coughs linked to minor throat and bronchial irritations, such as those that typically accompany the common cold or influenza.

What side effects are possible with Robafen Cough?

Possible Side Effects and Safety Information

This section describes the adverse reactions and essential safety constraints of Robafen Cough (Dextromethorphan Hydrobromide), as documented in government regulatory sources, such as the FDA and national drug agencies.

Officially Documented Adverse Reactions

Adverse reactions are categorized by the affected body system in regulatory documentation, though precise frequency categories (e.g., 'common,' 'rare') are not always provided in the Over-The-Counter (OTC) labeling. Reactions generally involve the following systems:

System-Organ Class (SOC) Examples of Listed Effects
Nervous/Psychiatric Dizziness, Drowsiness, Restlessness, Nervousness, Confusion
Gastrointestinal Nausea, Vomiting, Stomach Upset, Constipation
Dermatologic/Immune Skin rash, Hives (Urticaria), Itching, Severe Allergic Reactions (Anaphylaxis)

Serious Safety Considerations

Certain clinically significant events are noted in official warnings, typically associated with interactions or misuse:

  • Serotonin Syndrome: A potentially serious reaction documented as a risk when Dextromethorphan is combined with or used within two weeks of stopping prescription Monoamine Oxidase Inhibitors (MAOIs).
  • Severe Hypersensitivity: The possibility of severe allergic reactions (e.g., Anaphylaxis) is noted in regulatory documents.

Safety-Related Restrictions and Constraints

Official labeling defines specific limits and cautions for safe use:

  • Contraindication with MAOIs: Use is strictly forbidden while taking an MAOI or for 14 days after discontinuing an MAOI.
  • Chronic Cough Restriction: Should not be used for chronic cough associated with smoking, asthma, or emphysema, or for a cough that produces excessive phlegm, unless directed by a healthcare professional.
  • Impaired Alertness: Caution is necessary when driving or operating heavy machinery due to the potential for dizziness or drowsiness.

Population-Specific Notes

The label advises consulting a professional before use during pregnancy or breastfeeding due to the lack of definitive safety data. Caution is also indicated for individuals with known hepatic (liver) or renal (kidney) impairment.

Overdose and Emergency Response

Overdose involving the active ingredient in Robafen Cough (Dextromethorphan HBr) is documented by regulatory authorities as a serious medical event that requires immediate intervention.

Domain Official Regulatory Statements
Documented Manifestations Clinical signs may include a spectrum of Central Nervous System (CNS) effects such as drowsiness, confusion, ataxia, and hallucinations, escalating to seizures and coma. Ocular signs, including nystagmus and mydriasis, are also documented.
Severe Outcomes Overdose risks include potentially life-threatening systemic toxicities such as Serotonin Syndrome, rhabdomyolysis, and severe respiratory depression. In young children, apnea (no breathing) is specifically noted as a risk.
Immediate Action Official regulatory guidance mandates that users must Get medical help right away or call emergency services upon recognition of any overdose sign. All suspected exposures require urgent referral for professional assessment.

Official Overdose Management and Monitoring:

The management of overdose is centered on providing symptomatic and supportive treatment. Medical procedures documented in official labeling include monitoring of vital signs (e.g., blood pressure, breathing rate) and using specific interventions such as administering activated charcoal for gastrointestinal decontamination. In cases of severe CNS or respiratory depression, the potential use of Naloxone is noted as a documented measure.

Therapeutic Uses of Robafen Cough

What Robafen Cough Treats: Main Uses and Benefits


The primary role of Robafen Cough is to provide focused, symptomatic support by addressing specific cough patterns and their associated disruption to patient comfort. The medicine is commonly used to help with symptoms of a cough associated with conditions that may include the common cold or influenza (the flu).

Targeted Relief for Dry and Nonproductive Cough

This medication is relevant for easing nonproductive (dry) coughs that arise from minor irritation of the throat and bronchial passages. It is applied across domains where additional symptomatic support is needed, generally helping to address the repetitive, bothersome coughing characteristic of irritative states. The medication is commonly used to help with symptoms related to nonproductive coughs, minor throat irritation, and minor bronchial irritation.

Easing Discomfort and Supporting Rest

The medication is relevant for easing symptoms that interfere with daily functioning, and may assist with maintaining rest during episodes of heightened symptoms. By supporting the patient during these difficult episodes, the medication contributes to improved comfort. It is applicable in clinical settings that involve acute or unstable symptom patterns, such as when persistent coughing disrupts sleep.

Quick Fact: Relief for Dry Cough
This medication is applied in addressing nonproductive (dry) coughs associated with temporary respiratory irritations, and provides support that helps ease the overall symptom burden.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Robafen Cough (Dextromethorphan HBr) is strictly defined by regulatory guidelines based on age, pre-existing conditions, and simultaneous medication use.

Contraindicated Populations

Use is contraindicated and absolutely prohibited for individuals with a known hypersensitivity or allergy to dextromethorphan or any component of the formulation. It is also prohibited for patients who are currently taking, or have taken within the last 14 days, a prescription Monoamine Oxidase Inhibitor (MAOI), as this co-administration is a regulatory contraindication.

Age-Related Eligibility

The permissible age for use varies by product formulation, but the medicine is not recommended for children under 4 years of age according to official guidance. For many standard over-the-counter formulations, use is generally restricted to children 4 to 6 years and older and adults.

Conditional Use Restrictions

A healthcare professional must be consulted before use if the cough is chronic (persists or recurs) or is accompanied by excessive phlegm (mucus), as this may indicate a serious underlying condition. Caution is also warranted for patients with underlying chronic respiratory diseases, such as asthma or COPD. For individuals who are pregnant or breastfeeding, official labeling advises consulting a health professional before use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific constraints regarding the concomitant use of this product, which typically contains dextromethorphan, with several classes of medicines and substances.

Contraindicated Combinations and Serotonergic Agents

The most critical restriction is the absolute prohibition of concurrent use with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing MAOI treatment. This combination is classified as serious and potentially fatal due to the risk of serotonin syndrome.

  • Serotonergic Agents: Concurrent administration with other serotonergic medicines, such as Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), is associated with the risk of increased serotonergic effects and the development of serotonin syndrome.

Metabolic and Depressant Interactions

Interactions also arise from the metabolic pathway of dextromethorphan. Potent inhibitors of the CYP2D6 enzyme (e.g., fluoxetine, paroxetine, quinidine) can increase dextromethorphan concentrations, raising the risk of toxic effects and serotonin syndrome. Furthermore, the product may exhibit additive Central Nervous System (CNS) depressant effects when used with alcohol or other CNS depressant drugs, requiring avoidance of co-administration. Components like guaifenesin may also interfere with certain laboratory tests, potentially causing false results.

Mechanism of Action

The action of Dextromethorphan HBr, the active compound in Robafen Cough, is strictly confined to the central nervous system (CNS), focusing on receptor systems that govern the involuntary reflex. The mechanism explains the resulting change in the body's sensitivity to inputs that trigger the reflex.


Central Modulation of the Cough Threshold

The compound's core mechanism involves simultaneous agonism at the Sigma-1 (sigma1) receptor and non-competitive blockade of the excitatory NMDA receptor within the brain's medullary cough center. These molecular interactions initiate a cascade that significantly reduces the excitability of the neurons responsible for processing cough signals. This physiological dampening causes an elevation of the cough threshold, meaning a greater level of irritation is required at the periphery to initiate the motor command for the reflex.


Functional Scope and Mechanistic Constraints

While the central mechanism modulates the reflex, it is important to note its functional constraints. The mechanism lacks direct influence over peripheral physiological processes, such as mucus production or airway diameter. The compound, therefore, does not influence mechanisms related to the mobilization of secretions. Furthermore, the final expression of the antitussive effect can be subject to individual variations in the metabolic conversion of the parent drug to the active metabolite, dextrorphan, via the CYP2D6 enzyme.

Dosage and Administration Information

How to Use Robafen Cough

The usage of Robafen Cough, which contains Dextromethorphan HBr, involves specific parameters regarding administration route, dosing frequency, and course duration. This medicine is intended exclusively for oral administration as a liquid solution.

Official Dosing and Frequency

The established regimen for adults and children 12 years of age and over is typically 10 mg to 20 mg per dose. The dosing schedule requires administration every 4 hours (q4hr) or 6 to 8 hours (q6-8hr), depending on the specific formulation. A crucial constraint is the maximum daily dose, which must not exceed 120 mg of Dextromethorphan HBr in any 24-hour period.

Age Group Typical Single Dose Maximum Daily Limit
Adults and Children ge 12 Years 10 mg to 20 mg 120 mg
Children 6 to < 12 Years Reduced dose (e.g., 10 mg) Reduced maximum

Administration Requirements

Accurate measurement is mandatory, requiring the use of the dosing cup or specialized measuring device provided with the product, as household spoons can lead to inaccurate volumes. This medication is designated for short-term use, and the administration course should not exceed 7 days in total. Use for children under 4 or 6 years of age is generally not recommended or requires professional consultation. If a dose is missed, instructions typically advise taking the next dose as scheduled, without doubling the amount.

Recent Clinical Evidence

Research evidence / Overview of Studies for Robafen Cough

The research has examined Dextromethorphan HBr as a substance used in trials related to acute, nonproductive cough, a condition characterized by fluctuating or episodic manifestations associated with the common cold or other upper respiratory tract infections. The research base mainly consists of randomized controlled trials (RCTs), systematic reviews, and meta-analyses. These trials were designed to explore how symptoms change over defined time intervals.

Most research has explored short-term symptom changes in adult populations, structured to compare the active substance against a placebo. Researchers monitored outcomes like automated cough counts and patient-reported outcomes describing perceived discomfort. Reported results varied across these trials: objective measures often showed changes in cough reflex sensitivity measurements in controlled settings, but results for subjective symptom reports in real-world clinical settings were often observed to be similar to those reported for the placebo.

Research was evaluated in groups beyond the general adult population, including adolescents and younger children. Evidence in these groups remains limited, and the evidence quality varies across these specific populations. Subgroup findings are uncertain, and research provides limited insight into long-term patterns within these cohorts. Overall, evidence quality varies across studies, and most available evidence is related to short-term observation periods. Long-term effects are not fully established, as follow-up durations were limited to the acute duration of the respiratory illness.

The research does not determine whether an individual will respond similarly or provide individual predictions. The difficulty in separating observed changes from the influence of the natural course of the condition, combined with the strong placebo response, remains a factor in this research. Further comparative evidence and data for certain subgroups remain areas for ongoing research.

Key Studies & References

  1. Systemic review of randomized controlled trials of over the counter cough medicines for acute cough in adults
  2. Dextromethorphan: MedlinePlus Drug Information
  3. NICE Guideline NG120: Cough (acute): antimicrobial prescribing - Summary of the evidence (2019)

Frequently Asked Questions (FAQ)

Common questions about Robafen Cough (FAQ)

Q: Can Robafen Cough be taken with Tylenol or ibuprofen?

Regulatory guidance on Over-the-Counter (OTC) medicines advises checking all drug labels to prevent taking multiple products with the same active ingredients. Dextromethorphan (the active ingredient in Robafen Cough) does not typically interact directly with acetaminophen (Tylenol) or ibuprofen. Combining cold medicines carries a risk of accidental overdose or ingredient duplication. It is important to review all product ingredients to help prevent this risk.

Q: Can Robafen Cough be used by people with high blood pressure?

In some combination cold and cough products, a warning advises that people with pre-existing conditions like heart disease or high blood pressure should consult a healthcare professional before use. For single-ingredient Dextromethorphan products, this warning is generally absent, but official guidance advises that a healthcare professional be consulted before use when a person has a chronic condition.

Q: Are there any specific foods or drinks that should be avoided when taking Robafen Cough?

Official drug information explicitly states that alcohol should be avoided when taking Dextromethorphan (the active ingredient in Robafen Cough). This is because combining the two substances can result in additive Central Nervous System (CNS) depressant effects, which means it could increase effects like drowsiness or dizziness.

Q: Does Robafen Cough contain alcohol?

Specific product labels must be consulted to confirm the inactive ingredients. While official labeling advises avoiding alcohol due to interactions, many formulations of Robafen Cough are marketed as Alcohol-Free, as detailed in the inactive ingredient list of certain Over-the-Counter (OTC) labels.

Q: What is the difference between Robafen Cough and Robafen Cough Long-Acting?

Official OTC labeling differentiates formulations based on the frequency of administration. Long-acting Dextromethorphan products generally indicate a dosing interval that is intended to provide cough relief for up to 8 hours. In contrast, standard formulas typically require more frequent administration, such as every 4 hours.

Q: Can people who have diabetes use Robafen Cough liquid?

Many Dextromethorphan products are formulated to be Sugar-Free to accommodate users who must limit sugar intake. It is generally recommended to review the inactive ingredient list of the specific product. Some formulations may contain sugar substitutes or sugar alcohols like Sorbitol.

Q: Does Robafen Cough interact with common allergy medicines like Benadryl or Zyrtec?

Official drug information notes that Dextromethorphan can have additive CNS depressant effects when combined with other CNS depressants. This class includes some allergy medicines, such as those containing Diphenhydramine. Non-sedating antihistamines are typically not highlighted as carrying the same Central Nervous System (CNS) depressant risk.

Q: What is the typical duration of the cough relief provided by Robafen Cough?

The typical duration of the antitussive effect is generally indicated by the frequency of administration listed on the product label. For standard products, this is usually every 4 hours. For long-acting formulations, the label typically indicates relief for 6 to 8 hours.

Q: Are there different formulations or flavors of Robafen Cough?

Drug labels show that Dextromethorphan products may be available in various forms, including oral liquids (syrups) and sometimes gel caps or chewable forms. The oral liquids are frequently offered in different flavors (such as cherry or grape) to aid administration.

Q: Does Robafen Cough contain any common allergens like gluten or lactose?

Many formulations are marketed as Gluten-Free, and the active ingredient is not typically derived from common food allergens. Since the composition can vary between products, the full inactive ingredient list on the specific product label is the primary source to confirm the presence or absence of ingredients like gluten, lactose, or other potential allergens.

Q: How should I confirm if a different medication contains the same active ingredient as Robafen Cough?

Regulatory guidance for all Over-the-Counter (OTC) medicines indicates that the Drug Facts panel on the packaging is the place to check the active ingredients, such as Dextromethorphan HBr. This step helps users avoid accidental ingredient duplication when using multiple cold remedies.

Q: What are the possible visual side effects of the active ingredient in Robafen Cough?

Standard OTC labeling does not list visual disturbances among the common side effects. However, documented severe adverse events associated with high-dose use or toxicity of Dextromethorphan may include reports of visual disturbances or blurred vision.

Q: Is it common to feel a difference in taste after taking the liquid form?

The perception of a specific taste is common when taking oral liquid formulations. This is due to the presence of various flavoring agents (like artificial cherry or grape) listed in the inactive ingredients, which are included to mask the inherent taste of the drug.

Q: Can I use Robafen Cough if I have glaucoma?

While single-ingredient Dextromethorphan products do not typically carry a specific glaucoma warning, many cold medications that combine Dextromethorphan with other agents contain a general warning. This indicates that people with conditions like glaucoma are generally advised to consult a healthcare professional before use.

Q: Can Robafen Cough be taken with pain relievers that contain opioids?

Official drug interaction guidelines warn against combining Dextromethorphan with other Central Nervous System (CNS) depressant drugs. The opioid class of pain relievers is considered a CNS depressant. Combining these substances is described as potentially resulting in increased effects such as drowsiness or dizziness.

How should Robafen Cough be stored and disposed of?

How to Store and Dispose of Robafen Cough?

The official storage and disposal guidelines for this oral solution must be followed strictly to maintain its quality and prevent accidental exposure.

Storage and Handling

The medication must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Storage areas must be kept away from excess heat, moisture, and light. The liquid should not be refrigerated or frozen. To ensure product integrity, keep the medicine in its original container with the cap tightly closed.

Child Safety

It is a mandatory safety requirement to keep this medication out of the sight and reach of children.

Disposal Instructions

For disposal of unused or expired product, the best option is to use an official drug take-back program. If a take-back option is unavailable, the product should not be flushed down a toilet or drain. Instead, mix the medicine with an undesirable substance (such as used coffee grounds or cat litter), place it in a sealed bag or container, and discard it in the household trash, following US FDA guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Robafen Cough found in:

A-Z Index: